A Busy Week for Multiple Sclerosis News
It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
feature2
Annual Costs of Dementia Care Exceed GDP, New Report Says
If dementia care were a company, it would be the world’s largest in terms of annual revenue, surpassing even Wal-Mart.
European MedTech Summit 2010 a Conference to Watch
One of the most anticipated medtech conferences happening this fall is the 2nd European Tech Tour MedTech Summit, to be held September 29-30, 2010 in Lausanne, Switzerland.
Spotlight Back on Sudden Cardiac Arrest
Recent news reports of young American athletes collapsing on the field have drawn media attention to sudden cardiac arrest, a leading cause of death in the U.S.
No Shortage of Hopefuls in the Multibillion-Dollar Blood Thinner Business
Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
For Vax Providers, Flu Season Off to a Running Start
It’s flu season again, and more than 690,000 people in the U.S. have already been vaccinated, reports healthcare analytics service SDI.
Shire, Acceleron to Collaborate on Treatments for Rare Muscle Diseases
Shire Pharmaceuticals has signed a $498 million collaboration agreement with Acceleron Pharma to develop and commercialize treatments for muscular and neuromuscular disorders.
Americans Open to Using Mobile Health Devices, Report Finds
Americans are willing to use mobile devices to let physicians track their health, according to a new report from PricewaterhouseCoopers.
ZymoGenetics Acquisition Highlights Competitive Hepatitis C Treatment Race
Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.
Guiding Life Sciences Companies Along the Path to Success
Operating for over 50 years, Safeguard Scientifics is a holding company that provides capital, as well as strategic, operational and management resources for technology and life sciences companies.